UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Succession in family business: multi-source perspectives

Journal of small business and enterprise development, 2017-10, Vol.24 (4), p.753-774

2017

Volltextzugriff (PDF)

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

Osteoporosis international, 2015-02, Vol.26 (2), p.699-712

2015

Volltextzugriff (PDF)

Osteoporosis and Fracture Risk in Women of Different Ethnic Groups

Journal of bone and mineral research, 2005-02, Vol.20 (2), p.185-194

2005

Volltextzugriff (PDF)

Academic background and credibility in executive coaching effectiveness

Personnel review, 2014-08, Vol.43 (6), p.881-897

2014

Volltextzugriff (PDF)

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

Journal of bone and mineral research, 2011-02, Vol.26 (2), p.242-251

2011

Volltextzugriff (PDF)

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

JAMA : the journal of the American Medical Association, 2001-12, Vol.286 (22), p.2815

2001

Volltextzugriff (PDF)

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

JAMA : the journal of the American Medical Association, 2006-12, Vol.296 (24), p.2927

2006

Volltextzugriff (PDF)

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

Bone, 2000-11, Vol.27 (5), p.687-694

2000

Volltextzugriff (PDF)

Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting

Journal of bone and mineral research, 2017-11, Vol.32 (11), p.2304-2314

2017

Volltextzugriff (PDF)

Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

BMC musculoskeletal disorders, 2018-11, Vol.19 (1), p.392-392, Article 392

2018

Volltextzugriff (PDF)

Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension

Journal of bone and mineral research, 2004-08, Vol.19 (8), p.1259-1269

2004

Volltextzugriff (PDF)

Ecosystem-Based Fishery Management

Science (American Association for the Advancement of Science), 2004-07, Vol.305 (5682), p.346-347

2004

Volltextzugriff (PDF)

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

The New England journal of medicine, 2004-03, Vol.350 (12), p.1189-1199

2004

Volltextzugriff (PDF)

Defining and Measuring Servant Leadership Behaviour in Organizations

Journal of management studies, 2008-03, Vol.45 (2), p.402-424

2008

Volltextzugriff (PDF)

Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass

Journal of the American Geriatrics Society (JAGS), 2000-03, Vol.48 (3), p.241-249

2000

Volltextzugriff (PDF)

Leadership and Change Management: A Cross-Cultural Perspective

1, 2017

Volltextzugriff (PDF)

In Vitro and In Vivo Responses to High and Low Doses of Nitrogen-Containing Bisphosphonates Suggest Engagement of Different Mechanisms for Inhibition of Osteoclastic Bone Resorption

Calcified tissue international, 2013-06, Vol.92 (6), p.531-538

2013

Volltextzugriff (PDF)

Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment

Journal of bone and mineral research, 2002-12, Vol.17 (12), p.2222-2230

2002

Volltextzugriff (PDF)

Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting

Osteoporosis international, 2019-06, Vol.30 (6), p.1287-1295

2019

Volltextzugriff (PDF)

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

The New England journal of medicine, 1995-11, Vol.333 (22), p.1437-1444

1995

Volltextzugriff (PDF)

What Comes Around, Goes Around: Boards Need to Get Succession Planning Right to Avoid Boomerang CEOs

Board leadership, 2023-07, Vol.2023 (188), p.4-5

Santora, Joseph C.

2023

Volltextzugriff (PDF)

History of alendronate

Bone (New York, N.Y.), 2020-08, Vol.137, p.115411-115411, Article 115411

2020

Volltextzugriff (PDF)

Leaders and their use of motivating language

Leadership & organization development journal, 2014-01, Vol.35 (3), p.226-240

2014

Volltextzugriff (PDF)

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study

Osteoporosis international, 2014, Vol.25 (1), p.367-376

2014

Volltextzugriff (PDF)

Effect of alendronate and vitamin D3 on fractional calcium absorption in a double‐blind, randomized, placebo‐controlled trial in postmenopausal osteoporotic women

Journal of bone and mineral research, 2011-08, Vol.26 (8), p.1836-1844

2011

Volltextzugriff (PDF)

1 – 25 von 406

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(323)
Mit Volltextzugriff
(345)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Succession in family business: multi-source perspectives

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

Osteoporosis and Fracture Risk in Women of Different Ethnic Groups

Academic background and credibility in executive coaching effectiveness

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting

Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension

Ecosystem-Based Fishery Management

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

Defining and Measuring Servant Leadership Behaviour in Organizations

Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass

Leadership and Change Management: A Cross-Cultural Perspective

In Vitro and In Vivo Responses to High and Low Doses of Nitrogen-Containing Bisphosphonates Suggest Engagement of Different Mechanisms for Inhibition of Osteoclastic Bone Resorption

Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment

Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

What Comes Around, Goes Around: Boards Need to Get Succession Planning Right to Avoid Boomerang CEOs

History of alendronate

Leaders and their use of motivating language

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study

Effect of alendronate and vitamin D3 on fractional calcium absorption in a double‐blind, randomized, placebo‐controlled trial in postmenopausal osteoporotic women

Suchergebnisse filtern